Glytec Receives Another Patent Allowance for Therapy Advisor®

April 9, 2019

Glytec Therapy notes currently under development, the new product will extend the company’s core competencies beyond insulin optimization to include oral, inhaled and non-insulin injectable diabetes medications.

Glytec Therapy notes the patent allowance depicts the following key systems and methods: [highly abridged and consolidated]

  • A dosing controller comprising data processing hardware in communication with memory hardware periodically obtains, at the end of a reoccurring, configurable time interval, training data for a plurality of patients, including patient-state information such as age, gender, medical history, body mass index, risk factors and financial attributes; also, for those who use anti-diabetes medications: dose-combinations and a glycated hemoglobin measurement associated with each dose-combination, and for those who use insulin: blood glucose history, meal bolus doses administered during scheduled time intervals, and outcome attributes associated with each meal bolus dose. The data processing hardware then identifies for the plurality of patients included the training data, as applicable: optimum dose-combinations of anti-diabetes medications and/or optimum meal bolus doses of insulin for each scheduled time interval.
  • Upon receiving patient-state information for a new treated patient, the data processing hardware determines, as applicable, a next recommended dose-combination of anti-diabetes medications based on one or more of the optimum dose-combinations identified within the training data and/or a next recommended meal bolus dose of insulin for a scheduled time interval based on a combination of the meal bolus doses of insulin previously administered by the new treated patient and one or more of the optimum meal bolus doses of insulin identified within the training data. The data processing hardware then transmits the next recommended dose-combination of anti-diabetes medications and/or the next recommended meal bolus dose of insulin to a portable device configured to display the information to the new treated patient, and as applicable, automatically dial in the number of units of insulin and administer them to the new treated patient.

Glytec has grown its intellectual property portfolio to more than two dozen issued and allowed patents. “Developing cutting-edge innovations is a hallmark of Glytec’s DNA, and Therapy Advisor® is the latest example of that,” says Robby Booth, Senior Vice President Research & Development. “This newest allowance is one of many more to come, both domestic and international. We’ll be issuing additional announcements in the near future.”

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy